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Background: The unfavorable prognosis for locally advanced and metastatic head and neck 
squamous cell carcinoma (HNSCC) is primarily due to the resistance of cancer stem cells (CSCs) 
to radio-chemotherapy. ALDH (Aldehyde Dehydrogenase) has been used as a marker to identify 
CSCs in several tumors including HNSCC. Disulfiram (DSF) is a pan-ALDH inhibitor, which 
has been found to have remarkable anti-cancer activity. Moreover, DSF is a strong bivalent metal 
ion chelator, which binds copper (Cu
2+
) and is responsible for enhanced cytotoxicity.  
Methods: Cell viability was assessed using proliferation and apoptosis assays. A synergistic 
effect was defined by calculating the combination index (CI). ALDH activity was determined by 
ALDELUOR assay. Stemness-related transcription factors (TFs) were detected by qRT-PCR 
(Quantitative Real-time Polymerase Chain Reaction), and cellular self-renewal was measured by 
sphere- and colony-formation. Migration ability was performed by wound healing assay. Cell 
cycle and Reactive Oxygen Species (ROS) activity were analyzed by flow cytometry. 
Results: Our results showed a strong anti-proliferative effect of DSF in a dose- and time-
dependent manner, and Cu
2+
 addition dramatically enhanced cytotoxicity. DSF or DSF/Cu
2+
 
significantly reduced the proportion of ALDH 
high
 CSCs (e.g. from 59.8% to 33% and 30.0% in 
UM-SCC9) and stemness-related TFs. They reduced colony formation (e.g. from 145 to 72 and 
70 in UM-SCC9), spheroid formation (e.g. from 39 to 18 and 20 in UM-SCC9), and migration 
ability (e.g. from 71.85% to 42.1% and 43.49% in UM-SCC9). DSF or DSF/Cu
2+
 induced ROS 
generation and triggered cellular apoptosis. DSF or DSF/Cu
2+ 
abolished the cisplatin-induced 
cell cycle G2/M phase arrest (e.g. from 52.9% to 41.2% and 42.2% in UM-SCC9), overcame the 
resistance of cisplatin in ALDH 
high
 cells, and showed a synergistic effect in combination with 
cisplatin (CI<1). Combining radiation (IR) with DSF or DSF/Cu
2+
 showed a growth inhibition 
and attenuated the cell cycle G2/M phase arrest (e.g. from 53.6% to 40.2% and 41.9% in UM-
SCC9). Moreover, the triple treatment with DSF or DSF/Cu
2+
, cisplatin, and IR enhanced radio-
chemo sensitivity by inducing apoptosis (e.g. 42.04% and 32.21% in UM-SCC9) and ROS 
activity (e.g. 46.3% and 37.4% in UM-SCC9).  
Conclusions: Our data demonstrate that DSF or DSF/Cu
2+
 inhibits CSC properties by blocking 
ALDH enzymatic function. Furthermore, DSF or DSF/Cu
2+
 in combination with cisplatin and IR 
enhance cytotoxicity and induce ROS activity. Thus, our findings hold promise for pre- and 




Hintergrund: Die ungünstige Prognose des lokal fortgeschrittenen und metastasierten 
Plattenepithelkarzinoms im Kopf-Halsbereich (HNSCC) ist vor allem auf die Resistenz von 
Krebsstammzellen (CSCs) gegen die Radiochemotherapie zurückzuführen. ALDH (Aldehyde 
Dehydrogenase) wurde als Marker verwendet, um CSCs unterschiedlichen Tumoren, 
einschließlich HNSCC, zu identifizieren. Disulfiram (DSF) ist ein pan-ALDH-Hemmer, der eine 
bemerkenswerte Aktivität gegen viele Arten von Krebsarten aufweist. Darüber hinaus ist DSF 
ein starker bivalenter Metallionen-Chelator, der Kupfer (Cu
2+
) bindet und für eine erhöhte 
Zytotoxizität verantwortlich ist. 
Methoden: Die Zellvitalität wurde mit Hilfe von Proliferation - und Apoptose-Assays bewertet. 
Ein synergistischer Effekt wurde durch die Berechnung des Kombinationsindex (CI) definiert. 
Die ALDH-Aktivität wurde mittels ALDELUOR-Assay und FACS-Sortierung bestimmt. 
Stemness-related transcription factors (TFs) wurden mittels qRT-PCR (Quantitative Real-time 
Polymerase Chain Reaction) nachgewiesen und die zelluläre Selbsterneuerung mittels Spheroid- 
und Koloniebildungstests gemessen. Die Migrationsfähigkeit wurde durch einen 
Wundheilungstest bestimmt. Zellzyklus und Aktivität der Reaktiven Sauerstoffspezies (ROS) 
wurden mittels Durchflusszytometrie analysiert. 
Ergebnisse: Unsere Ergebnisse zeigten eine starke antiproliferative Wirkung von DSF in dosis- 
und zeitabhängiger Weise. Hunzufügen von Cu
2+
 führte zu einer drastisch erhöhten Zytotoxizität. 
DSF oder DSF/Cu
2+
 reduzierten den Anteil an ALDH-Hoch-CSCs (z.B. von 59,8% auf 33,0% 
und 30,0% in UM-SCC9) und stemnessbezogenen TFs deutlich. Sie reduzierten auch die 
Koloniebildung (z.B. von 145 auf 72 und 70 in UM-SCC9), die Sphäroidbildung (z.B. von 39 
auf 18 und 20 in UM-SCC9) und die Migrationsfähigkeit (z.B. von 71,85% auf 42,1% und 43,49% 
in UM-SCC9). DSF oder DSF/Cu
2+
 induzierten ROS-Bildung und lösten Apoptose aus. DSF 
oder DSF/Cu
2+
 haben den Cisplatin-induzierten Zellzyklus G2/M-Phasenstopp (z.B. von 52,9% 
auf 41,2% und 42,2% bei UM-SCC9) gestoppt, die Resistenz von Cisplatin in ALDH-
Hochzellen überwunden und einen synergistischen Effekt in Kombination mit Cisplatin (CI<1) 
gezeigt. Die Kombination von Strahlung (IR) mit DSF oder DSF/Cu
2+
 zeigte eine signifikante 
Wachstumshemmung und reduzierte den Zellzyklus G2/M-Phasenstopp (z.B. von 53,6% auf 
40,2% und 41,9% bei UM-SCC9). Darüber hinaus resultierte die Dreifachb ehandlung mit DSF 
oder DSF/Cu
2+
, Cisplatin und IR in einer erhöhte Radiochemosensitivität durch Induktion von 




Schlussfolgerung: Unsere Daten zeigen, dass DSF oder DSF/Cu
2+
 die CSCs-Eigenschaften 
hemmen, indem sie die enzymatische ALDH-Funktion blockieren. Darüber hinaus erhöhten DSF 
oder DSF/Cu
2+
 in Kombination mit Cisplatin und IR die Zytotoxizität und induzierten ROS-
Aktivität. Daher ermutigen unsere Ergebnisse DSF als Radio-Chemosensitizer in prä-klinischen 





















1.1 Head and neck squamous cell carcinoma (HNSCC) treatment 
Head and neck cancer is the sixth-most common cancer, accounting for over 550,000 new cases 
and 380,000 deaths worldwide per year [1], which can arise in the oral cavity, pharynx, larynx, 
nasal cavity, paranasal sinuses, thyroid, and salivary glands, and include a variety of 
histopathologic tumors. Among these pathological types, head and neck squamous cell cancer 
(HNSCC) is the most common one [2]. Despite HNSCC being highly curable at early stages, 
about 60% of HNSCC patients are diagnosed with loco-regionally advanced disease (stage III–
IV), which is still associated with poor curative prognoses, therefore, definitive local therapies, 
such as surgery, followed by radiation therapy (RT), with or without concomitant chemotherapy 
(CT), are the key components in the initial treatment of locally advanced (LA) HNSCC [3]. 
Although general treatment protocols and new advances are being optimized and intensified in 
the therapy of LA HNSCC, survival rates have remained largely unchanged over the past 30 
years, with a five-year overall survival rate of less than 50%, and treatment resistance as well as 
tumor recurrence remain the critical problems [4]. Thus, there is an urgent need for identification 
and development of novel therapeutic strategies, which are more effective and have fewer side 
effects than the currently used treatment regimens.  
The organ preservation protocol with chemo-radiation has been developed during recent years 
and is also increasingly being applied to LA HNSCC, whereby cisplatin-based chemotherapy is 
combined with concurrent loco-regional radiotherapy [5]. Cisplatin is a potent inducer of 
apoptosis in several cell types, and is also one of the most effective and widely used 
chemotherapeutic drugs for the treatment of human cancers, including HNSCC, especially at the 
advanced stage [6]. Biologically, cisplatin binds to DNA, forming adducts, and also favors the 
accumulation of intracellular free radicals [7]. Even though it has long history of successful use, 
cisplatin therapy has two major limitations — severe toxicity and acquired resistance [8]. 
Consequently, acquiring a better understanding of the molecular basis of cisplatin resistance is 
warranted in order to elucidate the underlying mechanisms of this drug resistant phenotype, 
which is the current primary obstacle to the clinical utility of this drug and improving the clinic 
outcome [9]. 
RT, either alone or in combination with concurrent systemic chemotherapy as appropriate, 
remains the mainstay standard of treatment in the curative-intent management of LA and 
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metastatic HNSCC, both in the definitive non-surgical and post-operative adjuvant settings [10, 
11]. Several types of DNA lesion are induced by IR, including changes in the bases of nucleic 
acids, single-strand breaks, double-strand breaks, and abnormal cross-links in DNA or between 
DNA and cellular proteins [12]. In response to DNA damage, proliferating cells arrest at specific 
checkpoints along the cell cycle, by activating a network of signaling pathways. Such pauses 
allow time for DNA repair and prevent the damaged DNA being replicated and transmitted to the 
next generation, either by reparation or by induction of cell death. The successful repair of DNA 
lesions is essential for clonogenic survival and the restoration of genome integrity. If not totally 
repaired, such lesions might be lethal for the cell, or may impair the integrity of genomic DNA. 
On the other hand, excessive and persistent DNA damage leads to premature senescence, 
apoptosis, necrosis or mitotic catastrophe [13-15]. In practice, one of the major challenges in RT 
is the prediction of the patients’ tumor radio-resistance in response to IR, in order to optimize the 
given dose for maximal tumor cell killing effect, and minimal normal tissue damage [16]. An 
adaptive response sometimes appears in cancer cells during the treatment process, and tumors 
showing an adaptive response tend to be more resistant, aggressive, and invasive [17]. Therefore, 
identifying the underlying mechanisms of radioresistance should a promising strategy to 
personalize therapy where necessary, thereby achieving better treatment success rates [18]. 
1.2 Cancer stem cells (CSCs) and stemness-related markers 
Cancer stem cells (CSCs) or cancer stem-like cells are a small population in the majority of 
tumor cells, which are responsible for tumor development, dissemination and recurrence [19]. 
They display high tumorigenicity and might associate with chemo-radio-therapy resistance in 
HNSCC. Although CSCs constitute a small minority of neoplastic cells, they are still believed to 
possess pluripotent and self-renewal capacity, thereby generating a heterogeneous cell population 
of the originating tumor, seeding at distant sites and driving the formation of macro metastasis 
[20]. Consequently, it is urgent to identify and develop unique agents to target CSCs, with 
potentially allows for increased specificity and efficiency in the clinic therapy, thereby enhancing 
patient survival. 
Based on the observations that CSCs contribute to cancer tumorigenicity, it has been suggested 
that the expression level of stemness genes, or core related factors to CSCs, may be associated 
with tumor progression. Recently, in vitro and in vivo research has also highlighted a number of 
stem-cell surface markers including CD44 and CD133, which could be isolated and measured by 
flow cytometry, and attribute tumorigenic properties to these CSCs, correlating with recurrence 
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and diagnosis in HNSCC [21]. Among these genes, the stemness-related TFs Oct3/4, Sox2, and 
Nanog form primary regulatory networks that coordinate to determine the self-renewal and 
differentiation of embryonic CSCs [22]. Studies demonstrate that Oct3/4 is highly expressed in 
human bladder cancer, and is associated with disease progression, increased metastasis, and 
lower survival [23]. Moreover, Nanog is over-expressed in numbers of cancer types, such as 
breast, lung, pancreas and ovary [24-27].  
Even though the survival of cells with CSC-specific properties in some carcinomas has been 
attributed to an enhanced ability for drug removal, decreased DNA damage, or increased DNA 
repair, the mechanisms behind their differential resistance to apoptosis are not yet completely 
clear, nor have they been investigated in a broad range of carcinomas or in normal human 
epithelium [28]. Therefore, it is crucial to get more information for their general applicability, 
especially in HNSCC, which is characterized by particularly high recurrence rates. 
1.3 Aldehyde dehydrogenase (ALDH) is a CSC marker and target for 
potential treatment 
The ALDH (Aldehyde dehydrogenase) family is a group of cytosolic isoenzymes that catalyze 
the oxidation of aldehydes and retinol in cells, and play significant roles in the cellular 
detoxification and controlling metabolism of retinoic acid (RA), primary for normal growth, 
differentiation, and development of adult organs and tissues in vertebrates [29]. Bertland et al. 
found that HNSCC with increased ALDH activity were more resistant to RT, and that the 
inhibition of ALDH activity increased sensitivity to IR [30]. Prince et al. also suggested that 
ALDH is a more specific marker for the CSC population than CD44 in HNSCC, which indicates 
that ALDH 
high
 cells comprise a cell subpopulation that are tumorigenic and capable of initiating 
tumors at very low numbers, and that ALDH on its own is a highly selective marker for CSCs 
[31].  
ALDH1A1, a core member of ALDH family, is a CSC cell-associated protein in various 
malignant cancers and its level correlates with the patient’s outcome [32]. Recently, ALDH1A1 
was found to be increased in tumor spheres [33], and in three-dimensional cultured cancer stem-
like cells [34] in esophageal squamous cell carcinoma cells, suggesting that ALDH1A1 might be 
a more reliable marker for the identification and isolation of CSCs. Furthermore, consistent with 
our findings, compared with other isoforms (ALDH1A3 and ALDH3A1), over-expression of 
ALDH1A1 enhanced lung cancer cell transformation. Additioinally, up-regulated expression of 
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ALDH1A1 is positively associated with the stage and grade of the lung cancer patients, and 
related to a poor prognosis [35].  
1.4 Anti-cancer effect of DSF or DSF/Cu2+ 
Disulfiram (tetraethylthiuram disulfiram, DSF), a member of dithiocarbamate family with a 297 
Da molecular weight, is an ALDH inhibitor that was used as a vermicide in the 1930s and for 
alcoholism in the 1940s [36, 37]. Accumulating evidence indicates that this existing drug has 
promising applications, exhibiting potent anti-cancer properties by enhancing conventional 
anticancer drug-induced apoptosis, decreasing angiogenesis, attenuating tumor growth, and 
reversing drug-resistance [20, 38]. In  the last few years, several both in vitro and in vivo studies 
have demonstrated that DSF is highly effective against a number of cancer types such as breast 
[39], glioblastoma [40], prostate [41], colorectal [38], and melanoma [42]. Furthermore, DSF 
also enhances the cytotoxicity of several anticancer drugs as well as RT, suggesting it as a 
potential chemo-radio-therapeutic agent [43]. Additionally, inhibition of ALDH activity has been 
demonstrated as a potential strategy to suppress CSCs, and the findings indicate that DSF may 
specifically target CSC subpopulations [44, 45].  
As a strong bivalent metal ion chelator, DSF converts to diethyldithiocarbamate (deDTC), and 
two molecules of deDTC bind to one molecule of copper (Cu
2+
) to form a complex Cu (deDTC)2 
(DSF/Cu) which improves the intracellular trafficking of copper and may probably responsible 
for DSF-induced apoptosis [46, 47]. Regarding the overall stoichiometry of reaction with respect 
to Cu
2+
, the DSF molar ratio is 0.9:1.0, which presumably could be a reference for ratio when 
DSF acts as a copper ionophore in the substance combination. It is likely that this may be the 
mechanism for the reaction of DSF with copper (II) ions under biological conditions [48]. 
Copper is indispensable in life processes, acting with an important effect in inflammation, tumor 
growth, and stimulating the proliferation and migration of endothelial cells at high 
concentrations [49, 50]. Moreover, Cu is an important trace element for life as it plays a core role 
in redox reactions, and triggers generation of reactive oxygen species (ROS) in human cells [47]. 
In comparison with their normal counterpart, head and neck tumor tissues contain higher levels 
of Cu [51]. Since basal Cu and intrinsic ROS levels are higher in the tumor cells, the use of DSF 
represents a potentially new approach to selectively target the cancer cells, limiting the cytotoxic 
effect associated with Cu overload against normal cells [52]. Consequently, the cytotoxicity of 
DSF/Cu
2+
 leads to the generation of oxidative stress, inhibition of DNA replication, or 
modulation of the activity of other critical cellular regulatory pathways [53]. 
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2. Aim of the study 
The objective of this thesis was to investigate the cytotoxicity of DSF or DSF/Cu
2+
 in HNSCC, 
their inhibitory effect on CSCs, and the promising mechanism involving the combination of 
chemotherapeutic agents (cisplatin) and IR in vitro. Therefore, the following aims were pursued: 
1. To explore the cytotoxic effect in HNSCC. 
2. To compare the expression of ALDH and stemness-related TFs (Oct3/4, Sox2, and Nanog) 
between monolayer-derived cells and their corresponding spheroid-derived cells. 
3. To characterize the inhibitory effect of DSF or DSF/Cu2+ on self-renewal capacity and CSC 
properties in HNSCC cell lines. 
4. To assess the combination effect of DSF or DSF/Cu2+, cisplatin, and IR in HNSCC cell lines 
and the potential mechanism for this combination through cell cycle distribution, cytotoxicity 
















3.1 Laboratory Equipment 
Freezer (-80°C, -150°C) Sanyo, Japan 
Axiovert 40C Microscope Carl ZEISS, Jena, Germany 
BD FACS Calibur System BD Biosciences, Germany 
Incubator Heraeus, Thermo Fisher Scientific, Germany 
Centrifuge Heraeus, Thermo Fisher Scientific, Germany 
Pipettes Eppendorf, Hamburg, Germany 
Thermocycler Julabo, Germany 













3.2 Chemicals and Reagents 
Universal Agarose Bio&SELL, GmbH, Nuremberg, 
Germany 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany 
70% Ethanol Carl Roth, GmbH, Germany 
Epidermal Growth Factor (EGF) Biochrom GmbH, Berlin, Germany 
Fetal Bovine Serum (FBS) Biochrom AG, Berlin, Germany 
Fibroblast Growth Factor-basic (bFGF) Biochrom GmbH, Berlin, Germany 
Penicillin/Streptomycin Biochrom GmbH, Berlin, Germany 
Phosphate Buffered Saline (PBS) Biochrom GmbH, Berlin, Germany 
Trypsin/EDTA Biochrom GmbH, Berlin, Germany 
Chloroform Merck KGaA, Darmstadt, Germany 
Isopropanol Biochrom GmbH, Berlin, Germany 
Trizol Reagent Ambion, Life Technologies, USA 
 
3.3 Human HNSCC Cell lines 
UM-SCC9, UM-SCC47, UMSCC11B: University of Michigan, MI, USA 
UT-SCC33: University of Turku, Finland 
3.4 Cell Culture Medium 
RPMI Medium 1640+GlutaMAX                                                                               Gibco, UK 
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Quantum 263                                                                      PAA Laboratories GmbH, Germany 
3.5 Kits and Other Material 
ALDEFLUOR Assay Kit Stemcell Technologies, Vancouver, Canada 
Annexin-V-FLUOS Staining Kit Roche, Mannheim, Germany 
Power SYBR Green Master Mix Thermo Fisher Scientific, MA, USA 
RevertAid First Strand cDNA Synthesis Kit Thermo Fisher Scientific, MA, USA 
Cell Proliferation Kit I (MTT) Roche, Mannheim, Germany 
MitoSOX Red Mitochondrial Superoxide 
Indicator 
Molecular Probes, Oregon, USA 
Caspase-3 Apoptosis Kit,  BD Bioscience, USA 
Cellstar Cell Culture Flasks Greiner Bio-One, Austria 
Corning Falcon Tissue Culture Dish Corning, NY, USA 
Falcon Polyptopylene Conical Tubes Corning, NY, USA 
Costar Cell Culture Plates (6-, 12-, 24, 96-
well) 
Corning, NY, USA 
Costar Ultra-low Attachment Cell Culture 
Plate (24-, 96-well) 
Corning, NY, USA 







4.1 Cell Culture 
Four HNSCC cell lines UM-SCC9, UM-SCC47, UMSCC11B, and UT-SCC33 were cultured in 
RPMI 1640 medium supplemented with 10% FBS (heat-inactivated at 56°C for 30 min) and 1% 
penicillin/streptomycin. Cells were maintained in a 37°C humidified incubator with 95% air and 
5% CO2. All cell experiments were performed in culture for experiments at 70-80% confluence. 
To harvest and passage them, cells were washed with PBS twice and detached with 0.5%/0.02% 
Trypsin/EDTA solution. Complete culture medium was added to stop the reaction. After 
centrifugation at 200*g for 5 min, cells were resuspended into new culture medium for future 
experiments.  
4.2 Drug preparation 
Free DSF and copper were dissolved in DMSO and distilled water, respectively, at a stock 
concentration of 10 mM, and stored at -20°C. Cisplatin was kept at a 3.3 mM concentration at 
room temperature. All drugs were freshly diluted into working concentrations with culture 
medium before use. A 1:1 ratio of DSF and Cu
2+
 was chosen for all the experiments. 
4.3 Spheroid formation assay 
First of all, the ultra-low attachment flasks were prepared. 8-10 ml of 1.5% agarose (dissolved in 
PBS) was filled into cell culture flasks. Then the monolayer cells were cultured in serum-free 
Quantum 263 supplemented with 10 ng/ml EGF and 10 ng/ml bFGF. 12-15 ml of the cell 
suspension was added into the cell plates and half of the new culture medium was supplied every 
2-3 days. For the passage, the culture medium was removed and the spheroids were harvested 
into a 40 μM cell strainer, followed by washing twice with PBS. The spheroids were dissociated 
into single cells using 0.5%/0.02% Trypsin/EDTA in 37°C water bath. After 5-10 min, complete 
culture medium was added to stop the reaction. All cells were filtered through the 40 μM cell 
strainer again and reseeded into fresh culture medium under the same conditions for the 
subsequent experiments.  
For the spheroid formation inhibition assay, cells were exposed to DSF or DSF/Cu
2+
 in a 24-well 
ultra-low attachment plate at a density of 2*10
4
 cells/ml for 3 days. Spheroids of 300 μM or 
more in diameter were calculated and photographed at 50-fold magnification. 
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4.4 MTT cytotoxicity assay and CI-isobologram analysis 
Assessment of the cytotoxic effect of DSF, DSF/Cu
2+
 or a combination with cisplatin or IR was 
performed, following 24-72 h of incubation at different drug concentrations, in all tested HNSCC 
cell lines. Single cells were seeded in triplicate into a 96-well plate at a density of 4000 cells/well 
in the 100 μl culture medium. Cells without any drug treatments were considered as controls. 
After the various treatment periods, 10 μl of MTT labeling reagent was added, including to 
controls, followed by incubation in a 37°C humidified atmosphere incubator with 95% air and 5% 
CO2 for 4 h. When the precipitate was clearly observed at the bottom of the plates, 100 μl of 
solubilization solution was added to all wells, mixed gently, and was finally incubated overnight. 
The solution absorbance was quantified at a wavelength of 595 nm using a Bio-Rad microplate 
reader.  
Cellular viability (%) was averaged and normalized against the untreated controls. Dose response 
curves and IC50 values were evaluated using GraphPad Prism 5.0 Software. The cytotoxic 
relationship between DSF and cisplatin was measured by Chou-Talalay method for drug 
combination, which is based on the median-effect equation. It provides the theoretical basis for 
the combination index (CI)-isobologram equation that allows quantitative determination of drug 
interactions, where CI<1, =1, >1 indicates synergism, additive effect, and antagonism, 
respectively. CompuSyn software was used for calculation at all doses or effect levels that were 
simulated automatically [54].  
4.5 Flow cytometric analysis for cellular apoptosis 
Cells were exposed to different treatments at a density of 3*10
4
/ml for various time intervals in a 
24-well plate. The apoptotic effect was measured using the Annexin-V-FLUOS staining kit 
according to the manufacturer’s guidelines. Cells were collected and resuspended in 100 μl 
labeling solution which contained 20 μl Annexin-V and 20 μl PI at a density of 1*107 cells/ml. 
Subsequently, cells were incubated at room temperature for 15 min in the dark.  
Cellular apoptosis and necrosis were determined using FL3 (PI) and FL1 (Annexin-V) by flow 
cytometry and measured using FlowJo V10 software. All the cells were divided into 4 quadrants: 


















4.6 Flow cytometric analysis for Caspase-3 activity 
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Cells were exposed to different concentrations of DSF or DSF/Cu
2+
 at a density of 3*10
4
/ml in a 
24-well plate. After 48 h, the apoptosis effect was defined by assessing Caspase-3 activity based 
on the manufacturer’s protocols. In brief, cells were incubated in BD Cytofix/CytopermTM 
solution for 20 min on ice. After washing twice, resuspend cells were labeled with specific 
antibody for 30 min at room temperature and were then analyzed by flow cytometry. 
4.7 Flow cytotmetric analysis for cell cycle 
Cells were treated with different concentrations of DSF, DSF/Cu
2+
, cisplatin, IR, or a 
combination at a density of 3*10
4
/ml in a 24-well plate for 48 h. Cells without any drug were 
used as controls. After the incubation time, cells were collected and washed with PBS twice and 
fixed in 70% cold ethanol at 4°C overnight. After washing with PBS again, cells were stained 
with 1 mg/ml PI, 10 mg/ml RNase, and 1% Triton at room temperature for 30 min in the dark. 
Specifically, in order to avoid cell lose after ethanol fixation, discarding the supernatant was 
done especially carefully and centrifuging was increased to 3000 rpm for 5 min.  
Flow cytometry was used to define the DNA content for all the samples. FlowJo software was 
used to analyze the percentage of cell cycle distribution in the G0/G1, S, and G2/M phases. 
4.8 Flow cytometric analysis for ROS activity 
After exposing to various drug treatments for 24 h, the cells were collected and incubated with 
MitoSOX Red reagent following the manufacturer’s instructions in a 37°C humidified incubator 
with 95% air and 5% CO2 for 15 min. Fluorescently labeled ALDH 
high
 and ALDH 
low 
samples, 
after cell sorting from Aldefluor stained populations, were immediately stained with MitoSOX 
Red reagent as described above. 
After the incubation time and washing with PBS twice, the mean fluorescence intensity was 
measured by flow cytometry. Cells without any drugs, but incubated with MitoSOX Red reagent, 
were used as controls. 
4.9 Irradiation (IR) 
Cells were pre-treated for 4-5 h with different exposures. Subsequently, IR was established with 
various dosages of 2, 4, 6, or 10 Gy using a medical linear accelerator with a 6 MV photon beam 
(2.76 Gy/min, Clinac 600 C/D, Varian, Palo Alto, CA, USA). All the cells, maintained in the cell 
culture plates, were positioned on a plastic foundation for backscatter saturation of the beam to 
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the plates. An 8 cm-thick solid block of a water-equivalent material was put on the top of the 
plates to ensure the photon dose exposure to the cells was homogenous. After 24 h, colony 
formation and ROS activity were determined, and 48 h later, the cell cycle distribution and 
apoptosis effect were analyzed. 
4.10 Clonogenic assay 
In the colony formation inhibition assay, cells were treated with DSF or DSF/Cu
2+
 for 24 h at a 
density of 3*10
4
/ml in 24-well plates. In the IR survival experiments, different treatments of cells 
were incubated in a 37°C humidified incubator with 95% air and 5% CO2 for an additional 24 h 
after IR. Then, cells were harvested and washed twice with PBS to make sure all the added drugs 
were completely removed. Single cells were reseeded in the fresh culture medium in 6-well 
plates. Cells without any treatment were included as controls. After 9-12 days, the medium was 
removed and colonies were washed with PBS twice before fixation by methanol and staining 
with 0.5% crystal violet. 
A cell population was defined as a colony by consisting of at least 50 cells. Plating efficiency 
(PE) was assessed as the number of colonies counted/ number of control cells planted. The 
survival fraction (SF) was the number of colonies observed, divided by the number of cells 
seeded, with a correction for the PE. The survival curves were determined using the linear-
quadratic-model (LQ-Model) and were calculated in the formula Y=exp(-(a*x+b*(x^2))) using 
GraphPad Prism software. 
4.11 Flow cytometric analysis for ALDH activity and cell sorting 
Assessment of ALDH enzymatic activity was performed by measuring the ALDH-mediated 
intracellular reaction of fluorescent compound ALDH substrate BODIPY-aminoacetaldehyde 
(BAAA), using the Aldefluor assay following the manufacturer’s protocols. In brief, all cells 
were harvest and resuspended in the buffer containing BAAA (1 μmol/L) at a density of 1*106 
cells in a 37°C humidified incubator with 95% air and 5% CO2 for 35 min. After the incubation 
time, cells were washed with PBS twice and analyzed by flow cytometry. 
Diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, was acted as negative control to 
establish the base line of fluorescence and to define the ALDH 
high
 population. 
For the cell sorting, cells were resuspended at a concentration of 1*10
7
 cells/ml after staining and 
sorted on an Aria cell sorter. The cells were kept on ice during all the procedures. The negative 
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controls treated with DEAB were assessed for background fluorescence and sorting gates. 
4.12 Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) 
Cells were collected following lysis in the trizol reagent, and total RNA was extracted with 
chloroform and isopropyl alcohol. Then the RNA was converted to cDNA using the RevertAid 
First Strand cDNA Synthesis Kit, flowing the manufacturer’s guidelines. qRT-PCR was 
established in a total 50 μl reaction volume including 1 μl cDNA and 25 μl Power SYBR Green 
Master Mix running on the StepOne system in triplicate. GAPDH was employed as a reference 
gene and the relative expression levels were calculated using the modified delta-delta method. 
The designed primer sequences of stemness-related TFs Oct3/4, Sox2, and Nanog were as 
follows: 
Oct-3/4: Forward: GACAGGGGGAGGGGAGGAGCTAGG 
Reverse: CTTCCCTCCAACCAGTTGCCCCAAAC 
Sox2: Forward: GGGAAATGGGAGGGGTGCAAAAGAGG 
Reverse: TTGCGTGAGTGTGGATGGGATTGGTG 
Nanog: Forward: TGCGTCACACCATTGCTATTCTTC 
Reverse: AATACCTCAGCCTCCAGC AGATG 
4.13 Wound healing assay 
In vitro wound healing assay, or so called scratch assay, is a popular, technically non-demanding 
and low-cost assay, which could be assessed with any readily available plates to measure the 
migration ability of the monolayer [55]. A confluent 24-well plate of monolayer cells was 
prepared, and then a “wound” was established by scraping off an area of cells using 1 ml plastic 
pipette tip. The non-attached cells were removed with PBS, and then covered with fresh medium 
containing 1% FBS and various exposures. 
All the samples were incubated in a 37°C humidified incubator with 95% air and 5% CO2, and 
wound areas were captured at 0 h and 24 h after scratching with an inverted microscope at 50-
fold magnification. Photographs were performed to measure the percentage of wound closure 
using Image J software as follows: Migrated surface area / Total surface area * 100%. 
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4.14 Statistical analysis  
GraphPad Prism 5.0 software was used for all statistical analysis. Values were represented as 
mean ± standard deviation (SD). Two-group comparison was evaluated using a two-tailed t-test. 
Comparison among multiple groups was quantified by one-way ANOVA. Two different 
categorical independent variables were calculated by two-way ANOVA. A probability level of 





















5.1 ALDH expression is higher in spheroid-derived cells (SDCs) versus monolayer-derived 
cells (MDCs) in HNSCC cell lines 
The Aldefluor assay has been successfully applied to detect the ALDH expression of CSCs in 
various cancer cells including HNSCC. Here, MDCs and SDCs from UM-SCC9, UM-SCC47, 
and UM-SCC11B were used to analyze ALDH enzymatic activity. As shown in Figures 1A and 
1B, cells treated with the specific ALDH inhibitor DEAB were used as internal negative controls 
to determine the background fluorescence, and to quantify the ALDH 
high
 population. We found 
that SDCs established a remarkably higher percentage of ALDH
 high
 cells versus parental MDCs. 




in SDCs was 49.8%, 45.6%, and 33.0% in the indicated cell 
lines, respectively, which had an approximately 2-3 fold increased expression compared to 
MDCs. 
5.2 Stemness-related TFs over-expressed in SDCs 
Recently, one study has shown that increased expression of Sox2 and Nanog was related to 
radio-resistance in HNSCC, which may be associated with the CSC-specific properties [56]. To 
determine if SDCs derived from HNSCC cell lines also share this stemness-related feature, we 
measured the TFs mRNA levels in SDCs and parental MDCs. As shown in Figure 1C, the 
expression of Oct3/4, Sox2, and Nanog were all observed as dramatically enhanced in SDCs 
versus MDCs. The highest increase was found in UM-SCC47 cell line, with an average increase 
of 11.64, 6.97, and 11.69 fold in the indicated TFs, respectively. Taken together, these findings 
proved that spheroid culture could enrich the CSCs and the increased stemness-related feature, 








Fig. 1: Expression of ALDH and stemness-related TFs in MDCs and SDCs. 
(A) Quantitation of CSCs by Aldefluor analysis. The region gate of ALDH 
high
 cells in MDCs (M) 
and SDCs (S) of the population is acquired by flow cytometry. DEAB, a specific ALDH inhibitor, 
was used as control. (B) Graphical representation of the statistical analysis of ALDH activity. 
*P<0.05, **P<0.01, t-test, compared to monolayer. (C) Relative increase of expression of TFs 
by qRT-PCR of SDCs. Bars in the diagram represent the increased fold in SDCs compared to 

































0.23 27.5 0.87 49.8
0.96 24.5 0.66 45.6
0.59 12.4 1.03 34.7

















































































5.3 DSF exhibits dose- and time-dependent cytotoxicity in HNSCC cell lines 
To explore the inhibitory effect of DSF in vitro, UM-SCC9, UM-SCC47, UM-SCC11B, and UT-
SCC33 were used for exposure to different concentrations of DSF from 0.001 to 100 μM for 72 h. 
No significant cytotoxicity was observed when the concentration was lower than 1 μM (Figure 
2A). Relative viability of the cells had a sharp drop at a concentration of 10 μM, and all cells 
were dead at 100 μM. The viability of cells was inhibited in a dose-dependent manner, and the 
cytotoxic effect enhanced linearly with increasing concentration of DSF in all indicated cell lines. 
The IC50 values were calculated: UM-SCC9: 13.96 μM; UM-SCC47: 13.43 μM; UM-SCC11B: 
11.24 μM; and UT-SCC33: 15.06 μM. 
We next measured the relationship between time and cytotoxicity by DSF in HNSCC cell lines. 
Cells were treated with various concentrations of DSF from 0.1 to 30 μM for 24 h, 48 h, and 72 h. 
We found that the average IC50 values in UM-SCC9 were 24.94, 18.74, and 15.32 μM; 21.91, 
16.62, and 15.69 μM in UM-SCC47; 32.10, 20.05, and 14.43 μM in UM-SCC11B; and 41.95, 
23.89, and 15.19 μM in UT-SCC33 in the different time courses, respectively. As shown in 
Figure 2B, a greatly higher value of IC50 than other time points was observed at 24 h in all tested 




 significantly increases cytotoxicity of HNSCC cell lines in a dose- and time-
dependent manner 
Although DSF alone had no obvious cytotoxicity until the concentration to 10 μM, as shown in 
Figure 1A, the cytotoxic effect of DSF was substantially increased with the supplement of Cu
2+
 
(Figure 2C). A significant decrease was found in the relative viability of the cells at a 
concentration of 0.3 μM in DSF/Cu2+. The DSF/Cu2+ complex showed remarkable increasing 
cytotoxicity, with the IC50 value of 0.24 μM in UM-SCC9, 0.193 μM in UM-SCC47, 0.267 μM 
in UM-SCC11B, and 0.27 μM in UT-SCC33, respectively, which  is nearly 50-fold lower versus 
DSF alone. 
We next assessed the apoptosis effect by DSF/Cu
2+
 exposure from 4 h to 72 h, with Annexin-V-
FLUOS staining kit using flow cytometry. The Annexin-V
+ 
population (upper-right and lower-
right quadrants) represent apoptotic cells. After treatment for 24 h or even longer, the 
dramatically enhanced cytotoxic effect was observed in all tested cell lines (Figure 2D and 2E). 
Taking together, these data suggested that the addition of Cu
2+
 to DSF significantly increases the 
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Fig. 2: Cytotoxicity of DSF or DSF/Cu
2+
 in HNSCC cell lines. 
(A) Cells were treated with various concentrations of DSF for 72 h and assessed by MTT assay. 
(B) Cells were treated with various concentrations of DSF (0.1-30 μM) at the indicated time 
intervals. The levels of IC50 were detected by MTT assay. *P<0.05, **P<0.01, one-way ANOVA, 
compared to 24 h. (C) Cells were treated with various combinations for 72 h and the viability 
was analyzed by MTT assay. (D) Cells were treated with DSF/Cu
2+ 
(1 µM/1 µM) at the indicated 
time intervals. The apoptosis population was measured by Annexin-V assay. **P<0.01, one-way 
ANOVA, compared to 4 h. (E) The percentage of the different cell populations discriminated by 
Annexin-V assay is given in each quadrant (Q). The Annexin-V
+
 populations (upper-right and 
lower-right) represent apoptotic cells. 
 








































5.5 DSF or DSF/Cu
2+
 induces apoptosis in HNSCC cell lines 
For the further measurement of cytotoxicity by DSF or DSF/Cu
2+
, the Caspase-3 activity was 
analyzed using flow cytometry. Cells were treated for 48 h with various concentrations of DSF 
from 1 to 100 μM and DSF/Cu2+ complex from 0.1 to 1 μM. The no drug control treatment 
induced a low apoptosis percentage of 10.3%, 16.0%, 11.6%, and 10.2% in the four indicated 
cell lines, respectively. As is shown in Figure 3A and 3B, after exposure to 10 μM DSF, the 
Caspase-3 activity was induced to 24.4%, 35.3%, 32.6% and 21.6%, respectively. When the 
concentration of DSF was enhanced to 100 μM, a significantly high expression of Caspase-3 was 
detected as 82.2%, 84.0%, 88.8%, and 77.4%, respectively. Furthermore, the supplement of Cu
2+
 
induced Caspase-3 activity to 61.8% in UM-SCC9, 67.7% in UM-SCC47, 74.5% in UM-
SCC11B, and 53.0% in UT-SCC33, respectively. In conclusion, these findings confirm again that 
DSF itself enhances apoptosis in a dose-dependent manner, while the Cu
2+
 supplementation 











































































































































































































































Fig. 3: DSF or DSF/Cu
2+ 
induces apoptosis in HNSCC cell lines. 
(A) Cells were treated with various concentrations of DSF or DSF/Cu
2+
 for 48 h, and then 
Caspase-3 activity was detected by flow cytometry. *P<0.05, **P<0.01, one-way ANOVA, 
compared to control. (B) The Caspase-3 activity was assessed by flow cytometry. The red lines 



























































5.6 No significant cell cycle distribution effect by DSF or DSF/Cu
2+
 in HNSCC cell lines 
The underlying mechanism of DSF or DSF/Cu
2+
 cytotoxicity is still not fully clear, therefore the 
cell cycle distribution was performed to measure the effect of DNA damage. Because the cell 
cycle phases could be compromised and disappear at high drug dosages, the concentrations used 
were set based on the IC50 values of each cell line required to avoid excessive apoptosis. Cells 
were exposed to various concentrations of DSF from 0.1 to 3 μM, or DSF/Cu2+ complex from 
0.01 to 0.1 μM for 72 h, then the cell cycle was established by flow cytometry. Cells cultured 
without any treatment were used as controls. No significant changes were observed in the 
proportion of cells in the G1, S, and G2/M phases (Figure 4). Therefore, these findings 
demonstrate that DSF or DSF/Cu
2+
 could not act in a core role in altering the cell cycle in the 
chosen settings. 
 
Fig. 4: No significant cell cycle distribution effect by DSF or DSF/Cu
2+ 
in HNSCC cell lines. 
The cell cycle distribution of cells after DSF or DSF/Cu
2+ 
exposure for 72 h was detected using 
flow cytometry. The numbers in the graphs represent proportions as percentages of sub-G1 























































































5.7 DSF or DSF/Cu
2+ 
triggers ROS generation in HNSCC cell lines 
Because DSF could inhibit ALDH activity, which acts as a ROS scavenger, we hypothesize that 
the cytotoxic effect of DSF or DSF/Cu
2+
 might be based on the generation of ROS in HNSCC 
cell lines. To test this hypothesis, cells were treated with various concentrations of DSF from 1 to 
100 μM, or DSF/Cu2+ complex from 0.1 to 1 μM. 24 h later, all cells were harvested and 
analyzed using flow cytometry. Similar to the induction cytotoxicity, the ROS activity was 
induced by increasing the concentration of DSF or DSF/Cu
2+
 (Figure 5A and 5B). After exposure 
to 10 μM of DSF, the ROS generation was increased to 33.1% in UM-SCC9, 35.1% in UM-
SCC47, 36.9% in UM-SCC11B, and 31.2% in UT-SCC33, respectively. When the concentration 
was enhanced to 100 μM, a remarkably high ROS activity was detected: 98.1% in UM-SCC9, 
97.6% in UM-SCC47, 97.9% in UM-SCC11B, and 98.5% in UT-SCC33, respectively. In 
addition, 1 μM DSF/Cu2+ complex could significantly increase the accumulation of ROS, which 
was seen to have the equivalent effect at the concentration of 100 μM DSF. Based on these 
observations, we conclude that the cytotoxic effect of DSF corresponds to intracellular ROS 
generation, while DSF/Cu
2+























































































































































































































Fig. 5: DSF or DSF/Cu
2+ 
triggers ROS generation in HNSCC cell lines. 
(A) Cells were treated with various concentrations of DSF or DSF/Cu
2+
 for 24 h, and then ROS 
activity was detected using flow cytometry. *P<0.05, **P<0.01, one-way ANOVA, compared to 











































23.4 29.6 33.1 27.6 97.1
25.6 29.0 35.1 97.6 28.9 94.9
27.9 29.9 36.9 97.9 29.8 97.6





5.8 DSF or DSF/Cu
2+
 inhibits ALDH enzyme activity in SDCs 
To evaluate the effective targeting of CSCs by DSF or DSF/Cu
2+
, the ALDH activity was 
determined in SDCs derived from tested HNSCC cell lines. As shown in Figure 6A and 6B, cells 
were treated with 10 μM DSF or 0.15 μM DSF/Cu2+ for 72 h, and then the percentage of ALDH 
high
 cells was significantly decreased from 59.8% to 33% and 30.0% in UM-SCC9, 41.8% to 21.2% 
and 20.0% in UM-SCC47, and 44.5% to 30.8% and 29.4% in UM-SCC11B, respectively. DEAB, 
a specific ALDH inhibitor, acted as a negative control to establish the ALDH 
high
 population and 
the background of fluorescence intensity. 
5.9 DSF or DSF/Cu
2+
 inhibits the expression of stemness-related TFs in SDCs 
As we had demonstrated that the SDCs expressed significantly higher levels of stemness-related 
TFs in HNSCC cell lines, we further investigated the inhibition effect of DSF or DSF/Cu
2+
 on 
SDCs by analyzing the CSC markers of Oct3/4, Sox2 and Nanog. From the analysis described in 
Figure 6C, it is clear that the TFs expression is remarkably decreased compared to untreated 
samples after treatment with 10 μM DSF or 0.15 μM DSF/Cu2+ for 72 h. The highest drop was 
detected in UM-SCC9, with an average of 0.33 or 0.39 fold in Oct3/4; 0.20 or 0.63 fold in Sox2; 
and 0.39 or 0.25 fold in Nanog, in DSF or DSF/Cu
2+
, respectively. Collectively, these results 
provide strong evidence that DSF reduce CSC-associated features, and the addition of Cu
2+
 













Fig. 6: DSF or DSF/Cu
2+ 
inhibits ALDH expression and stemness-related TFs expression of 
SDCs in HNSCC cell lines. 
























































































































































exposure for 72 h. DEAB, a specific ALDH inhibitor, was used as control. The numbers in the 
graph represent percent of ALDH 
high
 cells in the population acquired by flow cytometry. (B) 
Graphical representation of the statistical analysis of ALDH activity. **P<0.01, one-way 
ANOVA, compared to untreated control. (C) SDCs were exposed to DSF 10 µM or DSF/Cu
2+
 
0.15 µM for 72 h, mRNA was quantified for expression of the indicated panel of TFs. *P<0.05, 
**P<0.01, two-way ANOVA, compared to untreated control. 
5.10 Inhibition of colony formation by DSF or DSF/Cu
2+
 in HNSCC cell lines 
The clonogenicity assay was established to explore the cellular reproductive stemness capacity 
of cancer cells after various exposures. In this study, we investigated whether DSF or DSF/Cu
2+
 
could inhibit this clonogenic capacity. Compared to no-drug treatment controls, the numbers of 
colony-formation units were decreased from an average of 145 to 72 and 70 in UM-SCC9, 140 
to 80 and 68 in UM-SCC47, and 138 to 75 and 67 in UM-SCC11B, respectively, after exposure 
to 3 μM DSF or 0.1 μM DSF/Cu2+ complex in all tested cell lines (Figure 7A). This result may 
be due to a slower growth of the surviving cells, leading to lower cell amounts, which do not 
reach the minimum standard that defines a colony. Taken together, these findings demonstrate 
that DSF could able to suppress clonogenicity in HNSCC cell lines and the Cu
2+
 supplement 
could reduce the concentration of DSF to increase this effect. 
5.11 Inhibition of spheroid formation by DSF or DSF/Cu
2+
 in HNSCC cell lines 
Spheroid-derived cells (SDCs) are considered to enrich CSCs or cells with stemness-related 
characteristics. To investigate the proliferative potential of CSCs and the ability of epithelial cells 
to grow anchorage independently, spheroid formation assay was performed. As shown in Figure 
7B, a large amount of spheroids were grown in untreated control cells in all tested cell lines. To 
gain a better understanding of the inhibition ability of DSF or DSF/Cu
2+
, cells were treated with 
10 μM DSF or 0.15 μM DSF/Cu2+ complex for 3-5 days and photographs were taken at 50-fold 
magnification. After the incubation time, small and inattentive spheroids and loose cellular 
aggregates were captured, this indicated that the ability of spheroid formation was significantly 
reduced. The average spheroid number was remarkably decreased from 39 to 18 and 20 in UM-
SCC9; from 42 to 21 and 24 in UM-SCC47; and from 36 to 19 and 17 in UM-SCC11B, 
compared to untreated controls, respectively. These results suggest that stemness inhibition could 
be achieved by DSF or DSF/Cu
2+




5.12 Inhibition of migratory ability by DSF or DSF/Cu
2+
 in HNSCC cell lines 
Cell migration plays a core role in various pathologic and physiologic processes across varieties 
of disciplines of biology including wound healing, inflammation, tumor growth and 
differentiation [57]. Consequently, we further evaluated whether DSF or DSF/Cu
2+
 exposure 
could inhibit cell migration ability in HNSCC cell lines using the wound healing assay. After 
exposure to 10 μM DSF or 0.15 μM DSF/Cu2+ complex, the percentage of wound area closure 
was analyzed at an interval 20 h in UM-SCC9 and UM-SCC47, and at 24 h in UM-SCC11B. 
Figure 7C summaries the noteworthy inhibitions of migration ability in all tested cell lines. The 
no-drug treated cells had closed the scratch by 71.85% in UM-SCC9, 73.78% in UM-SCC47, 
and 73.51% in UM-SCC11B. However, after treatment with DSF or DSF/Cu
2+
, the cells reduced 
the percentage of wound closure by only 42.1% and 43.49% in UM-SCC9; by 45.86% and 43.00% 
in UM-SCC47; and by 43.97% and 41.2% in UM-SCC11B, respectively, which demonstrated 
that DSF or DSF/Cu
2+













































































































































































































































            
 
Fig. 7: DSF or DSF/Cu
2+ 
inhibits colony formation, spheroid formation and migratory 
ability in HNSCC cell lines. 
(A) Cells were treated with various concentrations of DSF or DSF/Cu
2+
 for 24 h and then 
reseeded in drug-free medium for 9-12 days. Colonies with minimum of 50 cells or more were 










































compared to control. (B) Cells were exposed to DSF or DSF/Cu
2+
 for 72 h and representative 
images are shown (x50 magnification). The histogram shows the statistical analysis of spheroid 
numbers. **P<0.01, one-way ANOVA, compared to control. (C) Representative pictures indicate 
the migratory cells under different treatment conditions and time points (x 50 magnification). 
The graphical representation shows the statistical analysis of migratory ability. **P<0.01, one-
way ANOVA, compared to control. 
5.13 Increase of colony formation, spheroid formation, and decrease of ROS activity in 
ALDH 
high
 cells versus ALDH 
low
 cells 
Since ALDH has been reported previously as an important stem cell marker in HNSCC, the 
FACS-sorted ALDH 
high
 and ALDH 
low
 population were treated and analyzed for further 
investigation of CSC-features. The colony formation and the spheroid formation were 
established to measure the cell-renewal capacity of ALDH 
high
 and ALDH 
low
 cells. As shown in 
Figure 8A and 8B, the ALDH 
high
 population could form significantly greater numbers of 
colonies and spheroids compared to the ALDH 
low
 population in standard culture conditions, 
which indicates a property relating to tumor initiating ability. 
Furthermore, we evaluated the ROS activity in both ALDH 
high
 and ALDH 
low
 sorted cells. As 
shown in Figure 8C, ALDH 
high
 cells indicated a lower basal level of ROS accumulation because 
of higher expression of ALDH, which is a ROS scavenger to protect cells against oxidative stress. 
Additional, this difference between two population cells also suggested that ALDH 
low 
cell with 
rapid metabolism while ALDH 
high
 cells were more quiescent. In conclusion, these findings 
indicate that ALDH activity plays an essential role in HNSCC CSCs. 
5.14 DSF overcomes the resistance of cisplatin in ALDH 
high
 cells 
To investigate the significance role of ALDH in chemo-resistance, the relative viability of FACS-
sorted ALDH 
high
 and ALDH 
low
 cells were measured after treated with different concentrations 
of cisplatin. A significant difference of growth capacity between two populations was detected in 
Figure 8D. The ALDH 
high
 cell fractions showed more resistant to cisplatin treatment, particularly 
starting from lower concentration (1.25 μM), compared to the ALDH low cells. Nevertheless, 
when combined with 5 μM DSF, the cytotoxic effect of cisplatin in ALDH high cells was greatly 
enhanced. In conclusion, these findings prove that DSF could target HNSCC CSCs in the 
specifically highly enriched ALDH 
high
 population and increase the effectiveness treatment of 










































































































































































































































































Fig. 8: Analysis of stemness, ROS activity, and cisplatin sensitivity in ALDH-sorted cells. 
(A) ALDH 
high
 and ALDH 
low
 cells were cultured for 9-12 days. Colonies with minimum of 50 
cells or more were calculated. Histogram shows the statistical analysis of colony numbers. 
**P<0.01, t-test, compared to ALDH 
high
 cells. (B) ALDH 
high
 and ALDH 
low 
cells were cultured 
for 3-5 days. The graphical representation of the statistical analysis shows the spheroid numbers. 
**P<0.01, t-test, compared to ALDH 
high
 cells. (C) ROS activity of ALDH 
high
 and ALDH 
low
 
cells was detected by flow cytometry. **P<0.01, t-test, compared to ALDH 
high
 cells. (D) ALDH 
high
 and ALDH 
low
 cells were exposed to various concentrations of cisplatin, or in a combination 
of 5 µM DSF for 72 h and the viability was assessed by MTT assay. 
5.15 DSF and cisplatin combination induce synergistically cytotoxicity 
The combination of drugs could abolish treatment resistance compared to a single compound, 
thus it is meaningful to define the drugs that act synergistically. Next, we attempted to assess 
whether DSF could improve the sensitivity of HNSCC cell lines to cisplatin treatment. As shown 
in Figure 9A, when 5 μM DSF was added to different concentrations of cisplatin, the cytotoxic 
effect was increased substantially. 
To gain a better understating of the essence of these results, the combination index (CI) 
according to Chou-Talalay method was performed. As shown in Table 1, the combination of DSF 
and cisplatin established a synergistic effect in all tested HNCC cell lines at a broad level of 
ED50 and ED75 with CI<1. Taken together, these findings demonstrate that DSF decreases 
cellular viability synergistically and improves the cytotoxic effect of cisplatin treatment. 
5.16 DSF or DSF/Cu
2+
 abolishes cisplatin-induced G2/M phase arrest 
Based on the combination cytotoxicity affection in the previous experiments, we hypothesized 
that the mechanism might be related to the abolishment of the G2/M phase following the drug 
treatment. Therefore, the cell cycle distribution was performed after 48 h of exposure to cisplatin 
in the presence of DSF or DSF/Cu
2+
. As shown in Figure 9B and 9C, cisplatin (0.3 μM for UM-
SCC9 and UM-SCC47, 0.6 μM for UT-SCC33) increased G2/M activation, which was due to 
more cell blocking in the G2/M phase, and less in G1/G0. We observed a prominent G2/M phase 
increase from 30.0% to 52.9% in UM-SCC9, 31.3% to 56.4% in UM-SCC47, and 23.6% to 54.7% 
in UT-SCC33, respectively. Nevertheless, when cells combined with 5 μM DSF or 0.1 μM 
DSF/Cu
2+
, a significant reduction of the G2/M phase was recognized, with a parallel induction of 
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cells in the G1 phase. A dramatic attenuation was detected from 52.9% to 41.2% and 42.2% in 
UM-SCC9, 56.4% to 43.1% and 44.9% in UM-SCC47, and 54.7% to 42.3% and 45.6% in UT-
SCC33, respectively. Therefore, these results suggest that DSF or DSF/Cu
2+
 could abolish 
cisplatin-induced arrest, which is responsible for lower cell blocking in the G2/M phase resulting 
in apoptosis induction. 
 
Table 1: Combination treatment with DSF and cisplatin results in synergistic cytotoxic 
effect in HNSCC cell lines. 
 




UM-SCC 9 0.560 0.447 
UM-SCC47 0.676 0.624 
UM-SCC11B 0.543 0.551 
UT-SCC33 0.645 0.507 
 
a) Combination Index (CI) for the combination of DSF and cisplatin. CI=1 indicates an additive 































































































































































































































































































Fig. 9: Combination with DSF or DSF/Cu
2+
 and cisplatin in HNSCC cell lines. 
(A) Cells were treated with various concentrations of cisplatin and 5 µM DSF 
 
for 72 h and the 
cytotoxic effect was determined by MTT assay. (B) Cells were treated with DSF (5 µM), 
DSF/Cu
2+ 
(0.1 µM), cisplatin (UM-SCC9 and UM-SCC47: 0.3 µM; UT-SCC33: 0.6 µM) or a 
combination of both for 48 h. The cell cycle distribution was detected by flow cytometry. The 
numbers in the graph represent proportions as a percentage of sub-G1 (<2N); G1 (2N); S-phase 
(S); G2/M phase (4N); and aneuploid cells (>4N). (C) The percentage of cells in the G2/M phase 
is compared. 
##
P<0.01: cisplatin vs. control; *P<0.05: cisplatin vs. cisplatin+DSF or 
cisplatin+DSF/Cu
2+
; one-way ANOVA. 
5.17 Radio-sensitizing effect of DSF or DSF/Cu
2+
 
The cellular viability was evaluated to investigate the combination cytotoxicity of IR and DSF or 
DSF/Cu
2+
. Cells were pre-treated with various concentrations of DSF or DSF/Cu
2+
, then exposed 
to IR (10 Gy) and subsequently cultured for 72 h. The combined treatment was compared, and 
the results are shown in Figure 10A. When a combination of DSF or DSF/Cu
2+
 with IR was 
applied, the dose response curves showed a significantly enhanced cytotoxic effect. 
Furthermore, to determine whether DSF or DSF/Cu
2+
 could potentiate a radio-sensitizing effect 
in HNSCC cell lines, the cells pre-treated with 1 μM DSF or 0.1 μM DSF/Cu2+ were exposed to 
a graded dosage of IR. Cell survival fraction was performed using colony formation, which is a 
primary assay to define cellular “reproductive death” after drug exposure. As shown in Figure 
10B, combination with DSF or DSF/Cu
2+
 and IR inhibits cell survival at the indicated dosage. In 
conclusion, these findings indicate that DSF or DSF/Cu
2+
 could increase the cytotoxicity of IR 
leading to radio-sensitizing effects. 
5.18 Combination of DSF or DSF/Cu
2+
 attenuate IR-induced G2/M phase arrest 
One of the hallmarks of cellular responses to IR is the activation of the G2/M checkpoint to 
prevent cells with DNA damage from entering mitosis. Firstly, we investigated the cell cycle 
distribution with the increasing dosage of IR. As is shown in Figure 10C, after a relatively high 
dosage exposure, starting from 10 Gy, large amounts of cells were blocked in the G2/M phase 
(41.9% in UM-SCC9, 40.8% in UM-SCC47, and 45.4% in UM-SCC11B, respectively) 




To explore the potential nature of DSF or DSF/Cu
2+
 sensitized cells to IR, cell cycle distribution 
analysis was performed after combination exposure. Cells were pre-treated with 5 μM DSF or 
0.1 μM DSF/Cu2+ following exposure at 10 Gy IR. As shown in Figure 10D and 10E, a dramatic 
G2/M phase activation was detected after 48 h of IR with an increase from 27.7% to 53.6% in 
UM-SCC9 and from 28.2% to 50.0% in UM-SCC47, respectively, with a concomitant decrease 
in the G1 phase as well. However, when combined with DSF or DSF/Cu
2+
, it resulted in reducing 
the G2/M phase from 53.6% to 40.2% and 41.9% in UM-SCC9, and from 50.0% to 39.5% and 
39.7% in UM-SCC47, respectively. Taken together, these results provide strong evidence that 
DSF or DSF/Cu
2+
 could attenuate IR-induced G2/M phase arrest where checkpoints in the cell 




















































































































































Fig. 10: Radiosensitizing effect of DSF or DSF/Cu
2+
 in HNSCC cell lines. 
(A) Cells were pre-treated with various concentrations of DSF or DSF/Cu
2+ 
and then irradiated 
with 10 Gy. After 72 h, viability was analyzed using MTT assay. (B) Cells were pre-treated with 
DSF (1 µM) or DSF/Cu
2+ 
(0.1 µM) and then irradiated with 2-6 Gy. After 24 h, cells were 
reseeded in drug-free medium for 9-12 days. The surviving fraction at different dosages of IR 
was compared using the LQ-Model formula. (C) Cells were treated with the indicated dosages of 
IR. Cell cycle distributions were detected using flow cytometry 48 h later. The numbers in the 
graph represent proportions as a percentage of sub-G1 (<2N); G1 (2N); S-phase (S); G2/M phase 
(4N); and aneuploid cells (>4N). (D) Cells were pre-treated with DSF (5 µM) or DSF/Cu
2+ 
(0.1 
µM) and then irradiated with 10 Gy. 48 h later, the levels of each cell cycle phase were measured 
using flow cytometry. The numbers in the graph represent proportions as a percentage of sub-G1 
(<2N); G1 (2N); S-phase (S); G2/M phase (4N); and aneuploid cells (>4N). (E) The percentage 
of cells in G2/M phase is compared. 
##
P<0.01: IR vs. control; *P<0.05: IR vs. IR+DSF or 
IR+DSF/Cu
2+























































































































5.19 Cytotoxic effect by the triple treatment of DSF or DSF/Cu
2+
, cisplatin and IR in 
HNSCC cell lines 
In previous experiments, we proved that DSF or DSF/Cu
2+
 enhanced the cytotoxic effect of 
cisplatin and IR by abolishing the G2/M phase arrest in cell cycle. We next investigated the 
effect of triple exposure on the combination of DSF or DSF/Cu
2+
, cisplatin, and IR. As shown in 
Figure 11A and 11B, combining 5 μM DSF or 0.1 μM DSF/Cu2+ with 2.5 μM cisplatin increased 
apoptosis to 34.71% and 26.69% in UM-SCC9, 31% and 25.48% in UM-SCC47, 37.55%, and 
31.77% in UM-SCC11B, respectively, which indicated the induction of remarkably higher cell 
deaths compared to each treatment alone. Furthermore, the combination with IR indicated a 
significant enhancement of apoptotic cell death. A cytotoxic effect was detected in 
IR+cisplatin+DSF and IR+cisplatin+DSF/Cu
2+
 with 42.04% and 32.21%in UM-SCC9, 43.9% 
and 31.91% in UM-SCC47, 45.37% and 38.08% in UM-SCC11B, respectively. Collectively, this 
effect of suppressing cell growth and inducing apoptosis in triple combination provides a 
promising clinical treatment strategy to achieve a better chemo-radio-sensitizing effect in 
HNSCC. 
Fig. 11: DSF or DSF/Cu
2+ 
combined with cisplatin and IR enhance apoptosis in HNSCC cell 
lines. 
(A) Cells were pre-treated with DSF (5 µM), DSF/Cu
2+ 
(0.1 µM), cisplatin (2.5 µM), or a 
combination of both, then exposed to IR (10 Gy). After 48 h, apoptosis was detected using flow 
cytometry. (B) Graphical representation of the statistical analysis. **P<0.01: cisplatin+DSF vs. 
cisplatin or DSF; *P<0.05: cisplatin+DSF/Cu
2+ 













































































































































































































































Control DSF DSF/Cu2+ Cisplatin IR
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Control DSF DSF/Cu2+ Cisplatin IR
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Control DSF DSF/Cu2+ Cisplatin IR




5.20 Treatment with DSF or DSF/Cu
2+
, cisplatin, and IR induces ROS generation in 
HNSCC cell lines 
To gain a better understanding of the cytotoxicity in this triple treatment, we explored the 
generation of ROS after exposure to DSF or DSF/Cu
2+
, cisplatin and IR. As shown in Figure 12A 
and 12B, the combination 5 μM DSF with 2.5 μM cisplatin enhanced ROS activity to 38.7% in 
UM-SCC9, 35.8% in UM-SCC47, 35.9% in UM-SCC11B, respectively, compared to each 
treatment alone. IR also plays a core role in the accumulation of ROS. When combined with 10 
Gy IR, addition of cisplatin and DSF or DSF/Cu
2+
, further increasing ROS activity was observed 
with 46.3% and 37.4% in UM-SCC9, 44.0% and 32.5% in UM-SCC47, 46.3% and 34.7% in 
UM-SCC11B, respectively, compared to unirradiated samples. In conclusion, this evidence 
proves that the triple treatment of DSF or DSF/Cu
2+
, cisplatin and IR substantially enhance the 
ROS generation, which is responsible for the cytotoxic effect and might be emphasized as a 
potential method in HNSCC treatment. 
 
Fig. 12: DSF or DSF/Cu
2+ 
combined with cisplatin and IR induce ROS generation in 
HNSCC cell lines. 
(A) Cells were pre-treated with DSF (5 µM), DSF/Cu
2+ 
(0.1 µM), cisplatin (2.5 µM), or a 
combination of both, then exposed to IR (10 Gy). ROS activity was detected 24 h later using 
flow cytometry. The numbers in the graph represent the ROS activity. (B) Graphical 
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Patients with head and neck cancer encompass a heterogeneous group, and even with 
advancements in treatment options, the overall survival rate for patients with advanced disease 
has not changed substantially over recent decades [58]. Therefore, there is a pressing need to 
improve therapeutic efficacy and develop novel treatment strategies involved in increasing radio-
chemotherapy response, counteracting resistance, reducing toxicity and improving clinical 
outcome. CSCs are identified as a distinct tumor cell population, which play an important role in 
inherent cancer resistance to conventional treatments, such as CT or RT [59], and in accelerated 
repopulation and acquired resistance post treatment. They are now being identified and 
characterized in numbers of solid cancers including HNSCC [60], and highlighting their 
potential functions and cellular properties is being considered as promising targeted therapy that 
might enhance treatment response [61]. ALDH activity has been used as a marker to identify and 
isolate CSCs in a variety of tumors including HNSCC [62]. In recent years, accumulating 
evidence indicates that ALDH may not only be a surrogate CSC marker but also a functional 
target for anti-CSC chemo-radio therapy [30, 40]. 
As an irreversible pan-ALDH inhibitor, DSF is known to inhibit all currently identified cytosolic 
and mitochondrial ALDH isoforms. This inhibition is probably the basis of its property of 
sensitizing cells to cytotoxic treatment, and targeting this function might be a novel method for 
further clinical application, leading to abolish CSCs [63]. DSF and its derivative could form a 
DSF/Cu
2+
 complex which contributes to transporting Cu into cancer cells, thus overcoming the 
transporter-controlled regulation of intracellular Cu homoeostasis [40, 46]. Although the serum 
Cu concentration is elevated in cancer patients, the anticancer activity of DSF is dependent on 
Cu and many other researchers have demonstrated that Cu supplementation further enhances the 
antitumor effect of DSF in vitro and in vivo [64]. Our results show that the viability of HNSCC 
cells was inhibited by DSF, and the addition of Cu
2+
 further enhanced the cytotoxicity in a dose- 
and time-dependent manner. These findings were consistent with previous studies, in that DSF 
has anticancer activity, and cooper potentiates its activity in vitro and in vivo [65-67].  
It is accepted that stem-like cells usually over-express stemness-related markers such as Oct3/4, 
Sox2, and Nanog, where these genes play essential roles in the regulation of self-renewal and 
tumorigenicity in the CSC populations of many kinds of tumors [68]. In order to confirm the 
potential stemness phenotype, SDCs and parallel MDCs from HNSCC cell lines were performed 
to detect the expression of the CSC-specific markers. A significant up-regulation was detected in 
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SDCs, and furthermore, SDCs also displayed higher expression of ALDH. In conclusion, these 
findings proved the presence of a subpopulation of cells with stem-like properties has been 
identified in SDCs and DSF or DSF/Cu
2+
 complex could inhibit these CSC-features which is 
relevant for many properties of HNSCC CSCs, such as clonogenicity and spheroid-formation.  
Cell migration is defined as the movement of individual cells, cell sheets and clusters from one 
location to another [69]. The study of cell migration behavior in cancer research is of particular 
interest, as the main reason of death in cancer patients is related to metastatic progression. 
Consequently, methods in this investigating this are very useful research strategies for a wide 
range of disciplines in biomedical sciences, biology, bioengineering, and related fields [70]. 
Compared to other tools, the in vitro scratch assay is particularly suitable for studies on the 
effects of cell-matrix and cell-cell interactions on cell migration, mimicking cell migration 
during wound healing in vivo, and it is compatible with the imaging of live cells during 
migration to monitor intracellular events if desired [71]. Collectively, our current observations 
proved that DSF or DSF/Cu
2+
 could inhibit ALDH activity to abolish the proliferation and self-
renewal capacity of CSCs, and to suppress their migratory ability, resulting in the sensitizing of 
treatment in HNSCC cell lines. 
Furthermore, we characterized the ALDH-enriched population using Aldefluor assay followed by 
FACS sorting, to assess whether they display these CSC-features as well. We showed that ALDH 
high
 cell fractions have increased clonogenic ability, enhanced sphere-formation, lower ROS 
levels, and more cisplatin resistance compared to ALDH 
low
 cells. These findings indicate that 
ALDH activity plays an essential role in the drug-resistance and self-renewal capacity of CSCs. 
Our data has developed in conformity with the results from Raha’s group, who detected that the 
ALDH
 high
 populations share common properties with chemotherapy drug tolerant CSCs. They 
also suggest that ALDH activity might be one mechanism to protect the CSCs from toxic side 
effects of therapy and ROS [72]. Specifically, we additionally showed that a therapy-resistant 
subpopulation of CSCs, with a high expression of ALDH and cisplatin-resistance can 
preferentially be sensitized by DSF, which could be a chemo-sensitizer in HNSCC cell lines. 
Even though the therapeutic efficacy of DSF or DSF/Cu
2+
 was investigated in vivo and in vitro, 
complete remission was not achieved by mono treatment. To improve this therapeutic effect, 
drug combination might be considered, delivering a small molecular agent, DSF, to the tumor 
tissue to suppress CSCs, and standard anti-cancer reagent to target the bulk tumor cells. While 
cisplatin is currently one of the most common chemotherapeutic agents used in the treatment, its 
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success and efficacy wane because of therapeutic resistance. Our study showed a synergistic 
effect of DSF in the combination with cisplatin resulting in CI<1, and this associated with 
reduced cellular proliferation and enhanced cisplatin-induced cytotoxicity. 
Cancer cells show a deregulated cell cycle progression, with either overexpression of positive 
regulators, or inhibition of negative regulators, which provide them with unrestrained replication 
potential [73]. Deregulation of the cell cycle has been implicated in most human cancers and 
leads to cell proliferation, chromosome instability, and loss of genomic integrity [74]. The 
cytotoxicity of cisplatin is mediated by its interaction with DNA, resulting in the formation of 
DNA adducts which activate several signal transduction pathways and culminate in the 
activation of apoptosis [75]. IR induces various DNA-damage, but double-strand breaks are the 
most cytotoxic effects, which can perturb cell cycle progression at different stages, mainly 
inducing G2/M phase arrest [76]. This arrest provides time to repair DNA damage and to prevent 
mitotic catastrophes and apoptosis [77]. Many studies have shown that abrogation of the G2 
checkpoint can potentiate cell death induced by IR [78] or DNA-damaging agents [79], which 
supports the G2 checkpoint as a potential therapeutic target that may sensitize cells to chemo- 
and radio-therapy. 
We showed that the cell cycle was paused at the G2/M phase when cells were exposed to 
cisplatin, and additional treatment by DSF or DSF/Cu
2+
 could abolish this block leading to DNA 
damage, which is a mechanism for cell death. Moreover, after treatment with IR, the G2/M cell 
fractions were increased in a dose-dependent manner, which suggest elevated checkpoint 
activation in HNSCC cell lines in response to DNA damage. We next demonstrated that DSF or 
DSF/Cu
2+
 potentiated the efficacy of IR through abolishing the G2/M arrest, and then have the 
ability to inhibit IR-induced G2 checkpoint activation, which could lead more damaged cells to 
enter mitosis without appropriate repair, leading to cell death and thereby significantly enhancing 
the cytotoxic effect of IR. This hypothesis may contribute to an underlying mechanism for the 
radio-sensitization caused by DSF or DSF/Cu
2+
 in HNSCC cell lines. Furthermore, DSF or 
DSF/Cu
2+
 strongly inhibited HNSCC clonogenicity to such an effect that few colonies could be 
isolated, resulting in a linear response being shown with increasing dosage, and a curve 
established with this combination therapy. 
In comparison with normal tissues, cancer cells generally possess high ROS activity and can 
tolerate higher levels of ROS [80]. Our findings demonstrated that DSF or DSF/Cu
2+
 alone, or in 
a combination with cisplatin and IR, lead to a remarkable intracellular ROS burst, which may 
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result in the effect of reduced scavenging and less detoxification, and develop to be a novel 
method for treatment of CSC subpopulations and ultimately cancers. DSF or DSF/Cu
2+
 reduced 
the ROS tolerance by inhibiting ALDH and targeting CSCs in HNSCC cell lines. 
In addition, a number of clinical trials have been established to identify the promising anti-cancer 
activity of DSF. Phase II clinical trials were performed to investigate DSF in newly diagnosed 
glioblastoma multiform (NCT 01777919), and to measure the combination effect with cisplatin 
in metastatic non-small cell lung cancer (NCT 00312819). Other phase I trials in hormone 
refractory cancers with liver (NCT 00742911) and melanoma metastases (NCT 00256230), and 
prostate cancer (NCT 01118741), are still ongoing. 
Even though the impressive tolerance of DSF and its powerful anti-cancer capacity have been 
researched for years, very few successful cases had been reported in clinic [81]. The possible 
reason for this discrepancy might be that the pharmacokinetics and pharmacodynamics of DSF 
appear to highly variable among subjects. Surprisingly, clinical studies on the kinetics of DSF 
have shown that a single-dose administration of 250 mg DSF leads to a maximum serum 
concentration of approximately 1.3μM and can reach 1.4μM after repeated doses [82]. 
Consequently, the enrichment and metabolism of DSF in the liver become the bottleneck for its 
translation into the clinic therapy. The Nano-encapsulated DSF, such as liposomal- and poly 
lactic-co-glycolic acid (PLGA), were used to prevent these eliminations. The nano-precipitation 
method protects the thiol groups in DSF, extends its half-life in the blood from less than 2 min to 
over 7 h, and successfully delivers the intact DSF into tumor tissues [83, 84]. This modification 
of DSF would be a beneficial approach for its delivery and improve its stability during the 
process of position targeting. 
However, due to the time-consuming and high-cost procedures in the development of new 
therapeutic drugs, the rate of new approvals are still very low. Therefore, drug repurposing or 
drug repositioning, utilizing the previously unknown anti-cancer effects of “old” drugs, can be a 
promising strategy to identify prospective new therapeutic uses [85]. DSF has been used as an 
anti-alcoholism drug for over 60 years with acceptable pre-clinical and clinical acceptable side 
effects, and it could therefore be a valuable approach to repurpose it into a promising new anti-
cancer drug, or an adjuvant treatment for sensitization in combination with other therapies. 
In this study, we determined DSF or DSF/Cu
2+
 was cytotoxic by itself in a dose- and time- 
dependent manner, and investigated the effect of ROS generation, which might be the potential 
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underlying mechanism responsible for its anti-cancer activity in HNSCC cell lines. Moreover, 
we demonstrated significant inhibition of the expression in CSC markers, including Oct3/4, Sox2, 
and Nanog, decreasing the growth of CSCs as well as reducing their cellular self-renewal 
capacity. Of even greater interest, our comparative analysis assessed the inhibitory effect of DSF 
or DSF/Cu
2+
 on ALDH expression and migration ability, which may have also proved the 
systems for eliminating CSC-features. The combined DSF and cisplatin created a synergistic 
cytotoxicity in HNSCC cell lines, and DSF sensitized the cancer cells - especially the ALDH 
high
 
cells - effectively for cisplatin treatment, and reversed its resistance. Furthermore, we also 
demonstrated that DSF or DSF/Cu
2+
 could sensitize the effectiveness of IR and cisplatin 
treatment, which were associated with suppressing the survival fraction, abolishing the G2/M 
phase arrest in the cell cycle, improving the apoptotic rate and inducing ROS generation as well. 
Taken together, these observations indicated that DSF or DSF/Cu
2+
 could target CSCs and lead 
to stemness-related inhibition, which resulted in intrinsically cytotoxic, and chemo-radio-
sensitizing effects. Overall, our present work suggests that DSF has potentially important 
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